NCT03565393

Brief Summary

Dietary fiber, a non-digestible carbohydrate, used in decades for the beneficial effect on health with physiological importance because such compounds have low energy values. These indigestible carbohydrates generally reach the large intestine undigested and unabsorbed, they are often used in many functional and/or low-calorie food and beverages. Researchers have stated that dietary fiber especially digestive-resistant maltodextrin has innumerable beneficial effects on human health, such as improving intestinal regularity by increasing fecal bulk, stimulating peristalsis and shortening gastrointestinal transit time. Resistant maltodextrin (Fibersol-2) is a low viscosity, water-soluble, indigestible dextrin produced by the treatment of corn starch with acid, enzymes, and heat. Dietary fiber, a non-digestible carbohydrate, has been used in decades for the beneficial effect of health with physiological importance. In developing countries most of the diarrhea episodes occur during the first two years of life and till date antibiotics have been found to have no role in over seventy five percent of young childhood diarrhea. Toddler's diarrhea which affects children aged 6 to 60 months is known as chronic nonspecific diarrhea of childhood. The stool is frequently watery or loose and may have food particles in it. Despite the diarrhea, the child continues to grow and gain weight, remains active and has a normal appetite. The beneficial effects of resistant maltodextrin are well known in developed countries; however, data are lacking in developing countries. It has become imperative to know its safety, tolerability and acceptability in small children with or without diarrhea in developing countries such as in Bangladesh.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
92

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Mar 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 19, 2018

Completed
Same day until next milestone

Study Start

First participant enrolled

March 19, 2018

Completed
3 months until next milestone

First Posted

Study publicly available on registry

June 21, 2018

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2019

Completed
Last Updated

February 26, 2020

Status Verified

March 1, 2018

Enrollment Period

1 year

First QC Date

March 19, 2018

Last Update Submit

February 25, 2020

Conditions

Keywords

TolerabilityAcceptabilityFibersol-2Children

Outcome Measures

Primary Outcomes (2)

  • Duration of diarrhea

    Main outcome measure is duration of diarrhea

    72 hours

  • Stool consistency.

    Stool consistency measured by regular observation

    24 hrs

Study Arms (2)

Fibersol-2

PLACEBO COMPARATOR

Receive Fibersol-2 twice daily

Combination Product: Fibersol-2

Placebo

PLACEBO COMPARATOR

Receive placebo twice daily

Combination Product: Fibersol-2

Interventions

Fibersol-2COMBINATION_PRODUCT

A placebo-controlled, randomized; double-blind 2 arm trial

Fibersol-2Placebo

Eligibility Criteria

Age1 Year - 3 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children with acute watery diarrhea, 3 or more watery stool in any 24-hour period of \<7 days duration with none or some dehydration
  • Aged between 1-3 years, and
  • Received written consent from parents

You may not qualify if:

  • Children with bloody diarrhea, severe diseases (severe sepsis, meningitis, severe pneumonia with respiratory distress requiring intensive care and ancillary support such as oxygen inhalation, orophryngeal suction etc.
  • Child in a situation and could interfere with the optimal participation to the study or constitute a particular risk of non-compliance
  • Currently participating in another clinical trial, and
  • Parents refused to give written consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kumudini Medical College and hospital, Mirzapur, Tangail

Dhaka, 1212, Bangladesh

Location

Related Publications (13)

  • Hillemeier C. An overview of the effects of dietary fiber on gastrointestinal transit. Pediatrics. 1995 Nov;96(5 Pt 2):997-9.

  • Kishimoto Y, Kanahori S, Sakano K, Ebihara S. The maximum single dose of resistant maltodextrin that does not cause diarrhea in humans. J Nutr Sci Vitaminol (Tokyo). 2013;59(4):352-7. doi: 10.3177/jnsv.59.352.

  • Livesey G. Tolerance of low-digestible carbohydrates: a general view. Br J Nutr. 2001 Mar;85 Suppl 1:S7-16. doi: 10.1079/bjn2000257.

  • Bonnema AL, Kolberg LW, Thomas W, Slavin JL. Gastrointestinal tolerance of chicory inulin products. J Am Diet Assoc. 2010 Jun;110(6):865-8. doi: 10.1016/j.jada.2010.03.025.

  • Castillejo G, Bullo M, Anguera A, Escribano J, Salas-Salvado J. A controlled, randomized, double-blind trial to evaluate the effect of a supplement of cocoa husk that is rich in dietary fiber on colonic transit in constipated pediatric patients. Pediatrics. 2006 Sep;118(3):e641-8. doi: 10.1542/peds.2006-0090.

  • King DE, Mainous AG 3rd, Lambourne CA. Trends in dietary fiber intake in the United States, 1999-2008. J Acad Nutr Diet. 2012 May;112(5):642-8. doi: 10.1016/j.jand.2012.01.019. Epub 2012 Apr 25.

  • McGill CR, Fulgoni VL 3rd, Devareddy L. Ten-year trends in fiber and whole grain intakes and food sources for the United States population: National Health and Nutrition Examination Survey 2001-2010. Nutrients. 2015 Feb 9;7(2):1119-30. doi: 10.3390/nu7021119.

  • Fastinger ND, Karr-Lilienthal LK, Spears JK, Swanson KS, Zinn KE, Nava GM, Ohkuma K, Kanahori S, Gordon DT, Fahey GC Jr. A novel resistant maltodextrin alters gastrointestinal tolerance factors, fecal characteristics, and fecal microbiota in healthy adult humans. J Am Coll Nutr. 2008 Apr;27(2):356-66. doi: 10.1080/07315724.2008.10719712.

  • Ye Z, Arumugam V, Haugabrooks E, Williamson P, Hendrich S. Soluble dietary fiber (Fibersol-2) decreased hunger and increased satiety hormones in humans when ingested with a meal. Nutr Res. 2015 May;35(5):393-400. doi: 10.1016/j.nutres.2015.03.004. Epub 2015 Mar 18.

  • Guimaraes EV, Goulart EM, Penna FJ. Dietary fiber intake, stool frequency and colonic transit time in chronic functional constipation in children. Braz J Med Biol Res. 2001 Sep;34(9):1147-53. doi: 10.1590/s0100-879x2001000900007.

  • Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995 Jun;125(6):1401-12. doi: 10.1093/jn/125.6.1401.

  • Shahid ASMSB, Ahmed S, Dash S, Kishimoto Y, Kanahori S, Ahmed T, Faruque ASG, Chisti MJ. Is Fibersol-2 efficacious in reducing duration of watery diarrhea and stool output in children 1-3 years old? A randomized, parallel, double-blinded, placebo-controlled, two arm clinical trial. PLoS One. 2023 Jan 27;18(1):e0280934. doi: 10.1371/journal.pone.0280934. eCollection 2023.

  • Shahid ASMSB, Ahmed S, Renesa TT, Onni AT, Dash S, Kishimoto Y, Kanahori S, Ahmed T, Faruque ASG, Chisti MJ. Digestive tolerability and acceptability of Fibersol-2 in healthy and diarrheal children 1-3 years old at a rural facility, Bangladesh: Results from a four arm exploratory study. PLoS One. 2022 Sep 19;17(9):e0274302. doi: 10.1371/journal.pone.0274302. eCollection 2022.

MeSH Terms

Conditions

Diarrhea

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Mohammod Jo Chisti, MMed PhD

    International Centre for Diarrhoeal Disease Research, Bangladesh

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
A placebo-controlled, randomized; double-blind 2 arm trial to assess the efficacy of fibersol-2 in children with acute watery diarrhea.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: A placebo-controlled, randomized
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 19, 2018

First Posted

June 21, 2018

Study Start

March 19, 2018

Primary Completion

March 31, 2019

Study Completion

March 31, 2019

Last Updated

February 26, 2020

Record last verified: 2018-03

Locations